BSAC Spring Conference

Reigniting the AMR agenda

THIS CONFERENCE IS CPD ACCREDITED AND WILL BE AVAILABLE UNTIL 10 NOVEMBER 2022

HELD 10-11 MAY 2022. REGISTER NOW TO ACCESS THE RECORDED CONTENT

Dr Claudie Charbonneau

Dr Claudie Charbonneau is the Global Patient & Health Impact Lead for Pfizer Hospital, one of Pfizer’s largest units which impacts the lives of over 200 million patients annually. In this role she is responsible for the oversight of the health economics and outcomes research (HEOR), market access, pricing, patient value, and evidence generation strategy and implementation for the in-line/launch Anti-Infectives portfolio.

A key part of her role sees Claudie working with her team to find solutions that place Pfizer at the forefront of the fight against antimicrobial resistance. She drives initiatives that educate on the need for global recognition of the holistic value of antibiotics to achieve a sustainable environment and ensure access to new and existing antibiotics in the future. These initiatives range from education on how to implement successful stewardship programs, to ensuring appropriate use of antimicrobial treatments, to developing innovative economic models that evaluate the true cost of infection, beyond the costs of the individual treatments as well as incentivize antibacterial R&D. She served as an EFPIA representative on the IMI Drive-AB initiative and is an active member of the International Society for Pharmacoeconomics and Outcomes Research. She has published an extensive number of papers and abstracts, as well as lectured on epidemiology, health economics, and AMR. Dr. Charbonneau earned her Ph.D. in Biomedical Sciences from the University of Montreal, Canada where she majored in Epidemiology and Health Economics.

Top